Navigation Links
Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
Date:11/4/2008

Canadian companies team up in specialty biologics development

TORONTO and CHARLOTTETOWN, Nov. 4 /PRNewswire/ - BioVectra Inc. and Therapure BioPharma Inc. have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.

Over the past five years, BioVectra has been developing proprietary technologies for PEGylation as a mechanism for drug delivery. The partnership with Therapure builds upon BioVectra's expertise in the production of modified biologic molecules using a proprietary MPEG technology.

Therapure, from its 130,000 sq. ft facilities in Mississauga, Ontario, adds proprietary purification techniques and impressive formulation, fill, and finish expertise in biologics handling.

"We are very excited about working with BioVectra," said Thomas Wellner, President and CEO of Therapure Biopharma. "They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership."

"Our current program for drug development depends on finding the right partners," said Dale Zajicek, COO and VP of Business Development for BioVectra. "We know we have made a good choice in Therapure Biopharma and we look forward to working together to further the development and commercialization of this product."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: http://www.therapurebio.com

About BioVectra Inc.:

BioVectra Inc. is a growing Canadian biopharmaceutical company focused on contract manufacturing and product development of active pharmaceutical ingredients, pharmaceutical intermediates, and specialized bioreagents. Located in Prince Edward Island, BioVectra currently holds 8 Drug Master File filings and is an active supplier to most of the major pharmaceutical, biotechnology, and diagnostic companies in North America and Europe.

For more information, please visit: http://www.biovectra.com


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
2. Therapure Biopharma Inc. opens for business with first client contracts
3. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
6. CeNeRx BioPharma Completes $15 Million Series B Financing
7. Lilly Recognized as One of the Worlds Top Biopharmaceutical Employers
8. Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
9. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
10. Helix Biopharma Closes $11.4 Million Private Placement
11. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... Lady ... eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah sought ... a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help with ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell ... injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded ... healing and tissue regeneration. , The novel method, developed by WPI faculty members ...
(Date:5/24/2016)... ... 24, 2016 , ... Last week, Callan Capital, an integrated wealth management firm ... Future of San Diego Life Science event at the Estancia La Jolla Resort and ... event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem ...
(Date:5/23/2016)... , ... May 23, 2016 , ... The need for blood donations in South Texas ... by the South Texas Blood & Tissue Center, blood donations are on the decline. In ... and they are down 21 percent in South Texas in the last four years alone. ...
Breaking Biology Technology:
(Date:3/17/2016)... March 17, 2016 ABI Research, the ... the global biometrics market will reach more than ... increase from 2015. Consumer electronics, particularly smartphones, continue ... sensors anticipated to reach two billion shipments by ... Dimitrios Pavlakis , Research Analyst at ABI Research. ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):